switching between glp 1 agonists Outcomes in GLP-1 RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy GLP-1 Receptor Agonists at the
Description
Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline
The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.
Todays DietitianVol
We dont sell anything we wouldnt personally use
By 2030, the global prevalence of obesity is expected to reach one billion
What to eat to balance your blood sugar and lose weight
